Myocardial Ischemia Market Research Report - Global Forecast till 2027

Myocardial Ischemia Market: Information by Type (Symptomatic and Asymptomatic), Treatment & Diagnosis (Diagnosis and Treatment), End User (Hospitals & Clinics, Diagnostic Centers and Ambulatory Surgery Centers) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Global Forecast till 2027

ID: MRFR/MED/4355-CR | August 2019 | Region: Global | 135 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

The Global Myocardial Ischemia Market is expected to register a CAGR of 6.00% and is anticipated to reach USD 50,120.3 Million by 2023. Myocardial ischemia is a medical condition characterized by the insufficient blood flow to the heart muscle via coronary arteries, commonly resulting in chest pain.


Factors such as the high prevalence of coronary heart disease, rising incidence of diabetes, and lifestyle changes provide suitable backgrounds for the development of market growth. However, the high cost of therapeutic surgeries and side effects related to medications are projected to restrain the market growth during the forecast period.


Market Dynamics


Myocardial ischemia is a common occurrence and occurs with increased frequency in patients with diabetes due to cardiac autonomic dysfunction. According to a study published in the Endocrinology, Diabetes & Metabolism Case Reports journal in 2013, ~22% of the patients diagnosed with type 2 diabetes were estimated to suffer from Silent Myocardial Ischemia (SMI). Moreover, it is reported that the prevalence of diabetes has increased. This is illustrative by the fact sheet of the World Health Organization (WHO) published in 2017. According to it, the global prevalence of diabetes among individuals ages 18 years or more was about 8.5% in 2014. Thus, it is interpreted that the rising prevalence of diabetes provides a necessary driving force for the myocardial ischemia market to expand.


Global Myocardial Ischemia Market Size, by End User, 2017 (USD Million)  Myocardial Ischemia Market


 Source: MRFR Analysis


Segmentation


The global myocardial ischemia market has been segmented into type, treatment & diagnosis, and end user. By type, the market has been bifurcated into symptomatic and asymptomatic. Based on treatment & diagnosis, the market has been divided into diagnosis and treatment. Diagnosis segment has been further segregated into imaging and stress test. The treatment has been further divided into medications and surgery. By end-user, the market has been classified as hospitals & clinics, diagnostic centers, ambulatory surgery centers, and others. The hospitals and clinics accounted for a market value of USD 18,744.2 million in 2023.


Key Players


The prominent players in the global myocardial ischemia market are Taxus Cardium (US), ViroMed Co. Ltd. (Republic of Korea ), Edward Lifesciences (US), Daiichi Sankyo Company Limited (Japan), Boston Scientific Corporation (US), Merck KGaA (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK).


Some of the key strategies followed by the players operating in the global myocardial ischemia market were innovation, product development, acquisition, and expansion.


Asia-Pacific Myocardial Ischemia Market Share, by Country, 2017 (%)  Myocardial Ischemia Market


Source: MRFR Analysis


Regional Analysis


The global myocardial ischemia market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is estimated to dominate the global myocardial ischemia market during the forecast period. Americas accounts for the largest regional market owing to the rising prevalence of diabetes, obesity, physical inactivity, and excessive alcohol use among the population. The European market for myocardial ischemia is expected to be the second-largest during the forecast period. The high growth rate is due to the high incidence rate of cardiovascular diseases in Europe. According to the European Cardiovascular Disease Statistics 2017, 45% of deaths in Europe is due to cardiovascular diseases (CVD).


Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to the rising prevalence of diabetes. According to the Asian Diabetes Prevention Initiative, 60% of the world’s diabetic patient live in Asia. Such high incidences of diabetes that lead to silent myocardial ischemia are likely to fuel the market growth.


Moreover, in the Asia-Pacific region, China accounted for a market share of 23.5% in 2017. However, the Middle East and Africa are expected to observe slow growth due to less exposure to healthcare services and stringent government rules and regulations.


Key Updates



  • In July 2016, Angionetics Inc., a subsidiary of Taxus Cardium, entered into an agreement with Huapont Life Sciences covering a USD 3,000,000 investment, to support the Generx Phase 3 clinical and commercialization development program.



  • In February 2018Edwards Lifesciences Corporation received the CE Mark for its self-expanding CENTERA valve, thus enhancing its transcatheter heart valve therapy segment.



  • In August 2017, Boehringer Ingelheim Pharmaceuticals, Inc. received FDA approval for CyltezoTM (adalimumab-adbm).


Market Segmentation


Global Myocardial Ischemia Market, by Type



  • Symptomatic

  • Asymptomatic


Global Myocardial Ischemia Market, by Treatment & Diagnosis



  • Diagnosis

  • Treatment


Global Myocardial Ischemia Market, by End User



  • Hospitals & Clinics

  • Diagnostic Centres

  • Ambulatory Surgery Centres


Global Myocardial Ischemia Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • United Arab Emirates

    • Saudi Arabia

    • Oman

    • Kuwait

    • Qatar

    • Rest of The Middle East & Africa




Available Additional Customizations



  • Regulatory scenario


Intended Audience



  • Medical device manufacturers and distributors

  • Government research organizations

  • Hospitals and clinics

  • Regulatory agencies

  • Pharmaceutical companies



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 50,120.3 Million
  • 2027: Significant Value
  •   CAGR   6.00% (2017-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Treatment & Diagnosis, End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Taxus Cardium (US), ViroMed Co. Ltd. (Republic of Korea ), Edward Lifesciences (US), Daiichi Sankyo Company Limited (Japan), Boston Scientific Corporation (US), Merck KGaA (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK).
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Rising prevalence of diabetes
  • The increasing cases of coronary artery disease and diabetes
  • Growing awareness related to heart conditions
  • Technological advancement in treatments
  • Rising numbers of hospitals and healthcare infrastructure


  • Frequently Asked Questions (FAQ) :


    Myocardial ischemia market projected to grow at approximately 6.00% CAGR during the assessment period (2020-2027).

    The valuation of the global myocardial ischemia market is estimated to increase to USD 50,120.3 MN by the end of 2023.

    Increasing awareness about heart conditions, technological advancement in medical science, and rising numbers of hospitals & healthcare infrastructure, are major tailwinds pushing the growth of the global myocardial ischemia market.

    North America holds the largest share in the global myocardial ischemia market, followed by Europe and the Asia Pacific, respectively.

    ViroMed Co. Ltd. (Korea), Johnson & Johnson Services Inc. (US), Boehringer Ingelheim International GmbH (Germany), Taxus Cardium (US), Bayer AG (Germany), Daiichi Sankyo Company Limited (Japan), AstraZeneca (UK), Edward Lifesciences (US), Boston Scientific Corporation (US), Novartis AG (Switzerland), and Merck KGaA (Germany), are some of the top players operating in the global myocardial ischemia market.

    Myocardial Ischemia Market – Summary


    The global market for myocardial ischemia is all set to garner USD 50,120.3 million if it can maintain the momentum at the touted CAGR of 6% during the assessment period (2017-2023), reports Market Research Future (MRFR). Myocardial ischemia occurs when the blood flow to the heart is reduced due to some blockage and subsequently leads to cardiac arrest. Timely diagnosis and proper treatment will be instrumental in saving lives of patients.


    One of the major factors driving the market is the prevalence of coronary heart disease. The disease is characterized by the hardening and narrowing of the arteries that hinder the blood flow to the heart by building plaques (atherosclerosis). According to the Centers for Disease Control and Prevention (CDC), in 2017, coronary heart disease was the most common type of heart disease within the U.S., and around 366,000 people succumbed to this disease in 2015. Astonishingly, the number of people contracting this disease is spiraling high.


    Diabetic patients are more prone to this disease due to cardiac autonomic dysfunction. As per a study published in the Endocrinology, Diabetes & Metabolism Case Reports journal in 2013, 22% of the patients diagnosed with type 2 diabetes had shown symptoms of Silent Myocardial Ischemia (SMI). The number of people getting affected by diabetes is showing no sign of slackening down. This could also trigger the market growth.


    However, the high cost of the procedures is a barrier that could impede the market growth. Angioplasty and stenting, coronary artery bypass surgery, and enhanced external counterpulsation (EECP) are some of the methods used for myocardial ischemia, and most of them incur a high cost.


    Segmentation Analysis


    The global market of myocardial ischemia can be segmented by type, diagnosis & treatment, and end-user.


    By type, the market includes symptomatic, asymptomatic (silent), and others. In the U.S., American Heart Association reported that each year 3 to 4 million citizens can become a target of asymptomatic ischemia. Moreover, people with cardiac arrest history and diabetes are more susceptible to this type of ischemia. Hence, the rise in number of such patients each year and the segment dominates the market. Asymptomatic ischemia lead the market with 73.3% of the market share in 2017.


    On the basis of diagnosis, the market comprises imaging and stress test. The diagnosis segment covered 34.8% of the global market in 2017. Based on treatment, the market consists medications and surgery. The increasing number of ischemia patients requires proper treatment to lead a healthy life. Therefore, the largest market share is expected to be generated by this segment.


    Based on end-users, the market includes hospitals & clinics, diagnostic centers, pharmacies, academic institutes, and others. The advanced technologies allow hospitals & clinics to help the patient go through all the necessary steps. Hospitals & clinics are expected to touch the USD 18744.2 million mark during the review period at an impressive CAGR of 6.31%.


    Regional Analysis


    Region-wise the market is segmented into the Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA).


    The Americas are the flag-bearer, with an estimated market revenue of USD 18,130.3 million during the forecast period, the region is going to dominate the global market. The market is expected to grow with CAGR of 6.21%. North America solely accounted for 35.7% of the global market share in 2017. Obesity, sedentary lifestyle, increasing number of diabetes cases, and increasing alcohol consumption in the U.S. are factors that can boost the market demand further.


    Europe is the second largest market owing to the fact that the rate is people getting affected by cardiovascular diseases in Europe is pretty high. As reported by European Cardiovascular Disease Statistics in 2017, 45% of deaths in Europe occur due to cardiovascular diseases (CVD).


    APAC is the third largest market but expected to register the fastest growth rate of 6.42% during the assessment period. The region has the highest number of diabetic patients, with 60% of the world’s diabetic population living here. This daunting number poses a silent ischemic attack threat to the inhabitants in the region. Hence, the market could expect an unprecedented growth.


    Market Competition


    India, China, and Australia in APAC region are emerging as a possible market for myocardial ischemia. India is the fastest growing one in the healthcare segment. With a staggering CAGR of 22.87%, the market is expected to cross USD 280 billion by 2020. These possibilities in the region create further prospects for the established brand where they can expand their business. Australia also has a burgeoning patient population where around 643,000 adults had reportedly got affected by the disease in period of 2014-2015.


    Mostly, the vendors try to stay abreast in this competitive market by bringing in the latest technologies and innovations and implementing them in increasing their portfolio. Expansion of their business in various countries is another strategy employed to curb the share of the competition. For instance, Boston Scientific, Inc. with a vast product portfolio in the myocardial ischemia industry has started operating in more than a dozen countries. It has a considerable influence in markets of several countries such as North America, Europe, and the Middle East and Africa,


    The key players profiled in the market are Boston Scientific, Inc., Johnson and Johnson Services Inc. (Janssen Global Services, LLC.), Pfizer Inc., Bayer AG, AstraZeneca, Edward Lifesciences, Taxus Cardium, Merck KGaA, Novartis AG, Daiichi Sankyo Company Limited, and others.

    1 Report Prologue

    2 Market Introduction

    2.1 Introduction 16

    2.2 Assumptions & Limitations 16

    3 Research Methodology

    3.1 Research Process 19

    3.2 Primary Research 19

    3.3 Secondary Research 20

    3.4 Market Size Estimation 20

    4 Market Dynamics

    4.1 Introduction 22

    4.2 Drivers 23

    4.2.1 High Prevalence Of Coronary Heart Disease 23

    4.2.2 Rising Prevalence Of Diabetes 23

    4.2.3 Lifestyle Changes 23

    4.2.4 Drivers Impact Analysis 23

    4.3 Restraints 24

    4.3.1 High Cost Of Therapeutic Surgeries 24

    4.3.2 Side Effects Related To Medications 24

    4.3.3 Restraints Impact Analysis 24

    4.4 Opportunity 25

    4.4.1 Untapped Markets Of The Asia-Pacific Region 25

    4.5 Macroeconomic Indicator 25

    5 Market Factor Analysis

    5.1 Value Chain Analysis 27

    5.1.1 R&D And Designing 27

    5.1.2 Manufacturing 27

    5.1.3 Distribution & Sales 27

    5.1.4 Post-Sales Review 28

    5.2 Porter’s Five Forces Model 28

    5.2.1 Bargaining Power Of Suppliers 28

    5.2.2 Bargaining Power Of Buyers 29

    5.2.3 Threat Of New Entrants 29

    5.2.4 Threat Of Substitutes 29

    5.2.5 Intensity Of Rivalry 29

    5.3 Investment Opportunities 29

    5.4 Pricing Analysis 30

    5.5 Demand & Supply: Gap Analysis 30

    6 Myocardial Ischemia Market, By Type

    6.1 Introduction 32

    6.2 Symptomatic 33

    6.3 Asymptomatic 33

    7 Myocardial Ischemia Market, By Treatment & Diagnosis

    7.1 Introduction 35

    7.2 Diagnosis 37

    7.3 Treatment 37

    8 Myocardial Ischemia Market:, By End User

    8.1 Introduction 39

    8.2 Hospitals & Clinics 40

    8.3 Diagnostic Centers 40

    8.4 Ambulatory Surgery Centers 40

    9 Global Myocardial Ischemia Market, By Region

    9.1 Introduction 42

    9.2 Americas 43

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.2.1 North America 46

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.2.1.1 US. 48

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.2.1.2 Canada 50

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.2.2 South America 52

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.3 Europe 55

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.3.1 Western Europe 58

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.3.1.1 Germany 60

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.3.1.2 France 62

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.3.1.3 UK 64

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.3.1.4 Italy 66

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.3.1.5 Spain 68

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.3.1.6 Rest Of Western Europe 70

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.3.2 Eastern Europe 72

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.4 Asia-Pacific 75

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.4.1 Japan 78

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.4.2 China 80

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.4.3 India 82

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.4.4 Australia 84

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.4.5 Republic Of Korea 86

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.4.6 Rest Of Asia-Pacific 88

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.5 Middle East & Africa 91

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.5.1 United Arab Emirates 94

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.5.2 Saudi Arabia 96

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.5.3 Oman 98

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.5.4 Kuwait 100

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.5.5 Qatar 102

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    9.5.6 Rest Of The Middle East & Africa 105

    Myocardial Ischemia Market, By Type

    Myocardial Ischemia Market, By Treatment & Diagnosis

    Myocardial Ischemia Market:, By End User

    10 Competitive Landscape

    10.1 Introduction 109

    11 Company Profiles

    11.1 Taxus Cardium 111

    11.1.1 Company Overview 111

    11.1.2 Financial Overview 111

    11.1.3 Products Offering 111

    11.1.4 Key Developments 111

    11.1.5 SWOT Analysis 111

    11.1.6 Key Strategy 111

    11.2 ViroMed Co. Ltd. 112

    11.2.1 Company Overview 112

    11.2.2 Financial Overview 112

    11.2.3 Products Offering 113

    11.2.4 Key Developments 113

    11.2.5 SWOT Analysis 113

    11.2.6 Key Strategy 113

    11.3 Edwards Lifesciences Corporation 114

    11.3.1 Company Overview 114

    11.3.2 Financial Overview 114

    11.3.3 Products Offering 115

    11.3.4 Key Developments 115

    11.3.5 SWOT Analysis 115

    11.3.6 Key Strategy 115

    11.4 Daiichi Sankyo Company Limited 116

    11.4.1 Company Overview 116

    11.4.2 Financial Overview 116

    11.4.3 Products Offering 117

    11.4.4 Key Developments 117

    11.4.5 SWOT Analysis 117

    11.4.6 Key Strategy 117

    11.5 Boston Scientific Corporation 118

    11.5.1 Company Overview 118

    11.5.2 Financial Overview 118

    11.5.3 Products Offering 119

    11.5.4 Key Developments 119

    11.5.5 SWOT Analysis 119

    11.5.6 Key Strategy 119

    11.6 Merck KGaA 120

    11.6.1 Company Overview 120

    11.6.2 Financial Overview 120

    11.6.3 Products Offering 121

    11.6.4 Key Developments 121

    11.6.5 SWOT Analysis 121

    11.6.6 Key Strategy 121

    11.7 Novartis AG 122

    11.7.1 Company Overview 122

    11.7.2 Financial Overview 122

    11.7.3 Products Offering 123

    11.7.4 Key Developments 123

    11.7.5 SWOT Analysis 123

    11.7.6 Key Strategy 123

    11.8 Boehringer Ingelheim International GmbH 124

    11.8.1 Company Overview 124

    11.8.2 Financial Overview 124

    11.8.3 Products Offering 125

    11.8.4 Key Developments 125

    11.8.5 SWOT Analysis 125

    11.8.6 Key Strategy 125

    11.9 Johnson & Johnson Services Inc. (Janssen Global Services, LLC) 126

    11.9.1 Company Overview 126

    11.9.2 Financial Overview 126

    11.9.3 Products Offering 127

    11.9.4 Key Developments 127

    11.9.5 SWOT Analysis 127

    11.9.6 Key Strategy 127

    11.10 Bayer AG 128

    11.10.1 Company Overview 128

    11.10.2 Financial Overview 128

    11.10.3 Products Offering 129

    11.10.4 Key Developments 129

    11.10.5 SWOT Analysis 129

    11.10.6 Key Strategy 129

    11.11 AstraZeneca 130

    11.11.1 Company Overview 130

    11.11.2 Financial Overview 130

    11.11.3 Products Offering 131

    11.11.4 Key Developments 131

    11.11.5 SWOT Analysis 131

    11.11.6 Key Strategy 131

    11.12 Pfizer Inc. 132

    11.12.1 Company Overview 132

    11.12.2 Financial Overview 132

    11.12.3 Products Offering 133

    11.12.4 Key Developments 133

    11.12.5 SWOT Analysis 133

    11.12.6 Key Strategy 133

    12 Appendix

    12.1 Discussion Blue Print 135

    13 List Of Tables

    TABLE 1 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 32

    TABLE 2 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR SYMPTOMATIC TYPE 2020-2027 (USD MILLION) 33

    TABLE 3 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR ASYMPTOMATIC TYPE 2020-2027 (USD MILLION) 33

    TABLE 4 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 35

    TABLE 5 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 36

    TABLE 6 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 36

    TABLE 7 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR DIAGNOSIS, BY REGION 2020-2027 (USD MILLION) 37

    TABLE 8 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR TREATMENT, BY REGION 2020-2027 (USD MILLION) 37

    TABLE 9 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 39

    TABLE 10 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR HOSPITALS & CLINICS 2020-2027 (USD MILLION) 40

    TABLE 11 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR DIAGNOSTIC CENTERS 2020-2027 (USD MILLION) 40

    TABLE 12 GLOBAL MYOCARDIAL ISCHEMIA MARKET: FOR AMBULATORY SURGERY CENTERS 2020-2027 (USD MILLION) 40

    TABLE 13 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY REGION 2020-2027 (USD MILLION) 42

    TABLE 14 AMERICAS MYOCARDIAL ISCHEMIA MARKET: BY REGION 2020-2027 (USD MILLION) 43

    TABLE 15 AMERICAS MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 43

    TABLE 16 AMERICAS MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 44

    TABLE 17 AMERICAS MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 44

    TABLE 18 AMERICAS MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 44

    TABLE 19 AMERICAS MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 45

    TABLE 23 NORTH AMERICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 47

    TABLE 25 US MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 48

    TABLE 26 US MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 48

    TABLE 27 US MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 49

    TABLE 28 US MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 49

    TABLE 29 US MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 50

    TABLE 30 CANADA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 50

    TABLE 31 CANADA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 50

    TABLE 32 CANADA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 51

    TABLE 33 CANADA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 51

    TABLE 34 CANADA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 52

    TABLE 35 SOUTH AMERICA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 52

    TABLE 36 SOUTH AMERICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 52

    TABLE 37 SOUTH AMERICA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 53

    TABLE 38 SOUTH AMERICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 53

    TABLE 39 SOUTH AMERICA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 54

    TABLE 40 EUROPE MYOCARDIAL ISCHEMIA MARKET BY: REGION 2020-2027 (USD MILLION) 55

    TABLE 41 EUROPE MYOCARDIAL ISCHEMIA MARKET BY: TYPE 2020-2027 (USD MILLION) 55

    TABLE 42 EUROPE MYOCARDIAL ISCHEMIA MARKET BY: TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 56

    TABLE 43 EUROPE MYOCARDIAL ISCHEMIA MARKET BY: DIAGNOSIS TYPE 2020-2027 (USD MILLION) 56

    TABLE 44 EUROPE MYOCARDIAL ISCHEMIA MARKET BY: TREATMENT TYPE 2020-2027 (USD MILLION) 56

    TABLE 45 EUROPE MYOCARDIAL ISCHEMIA MARKET BY: END USER 2020-2027 (USD MILLION) 57

    TABLE 46 WESTERN EUROPE MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 58

    TABLE 47 WESTERN EUROPE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 58

    TABLE 48 WESTERN EUROPE MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 58

    TABLE 49 WESTERN EUROPE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 59

    TABLE 50 WESTERN EUROPE MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 60

    TABLE 51 GERMANY MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 60

    TABLE 52 GERMANY MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 60

    TABLE 53 GERMANY MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 61

    TABLE 54 GERMANY MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 61

    TABLE 55 GERMANY MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 62

    TABLE 56 FRANCE MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 62

    TABLE 57 FRANCE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 62

    TABLE 58 FRANCE MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 63

    TABLE 59 FRANCE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 63

    TABLE 60 FRANCE MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 64

    TABLE 61 UK MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 64

    TABLE 62 UK MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 64

    TABLE 63 UK MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 65

    TABLE 64 UK MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 65

    TABLE 65 UK MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 66

    TABLE 66 ITALY MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 66

    TABLE 67 ITALY MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 66

    TABLE 68 ITALY MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 67

    TABLE 69 ITALY MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 67

    TABLE 70 ITALY MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 68

    TABLE 71 SPAIN MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 68

    TABLE 72 SPAIN MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 68

    TABLE 73 SPAIN MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 69

    TABLE 74 SPAIN MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 69

    TABLE 75 SPAIN MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 70

    TABLE 76 REST OF WESTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 70

    TABLE 77 REST OF WESTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 70

    TABLE 78 REST OF WESTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 71

    TABLE 79 REST OF WESTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 71

    TABLE 80 REST OF WESTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 72

    TABLE 81 EASTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 72

    TABLE 82 EASTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 72

    TABLE 83 EASTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 73

    TABLE 84 EASTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 73

    TABLE 85 EASTERN EURPOE MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 74

    TABLE 86 ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY REGION 2020-2027 (USD MILLION) 75

    TABLE 87 ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 75

    TABLE 88 ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 76

    TABLE 89 ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 76

    TABLE 90 ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 76

    TABLE 91 ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 77

    TABLE 92 JAPAN MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 78

    TABLE 93 JAPAN MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 78

    TABLE 94 JAPAN MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 78

    TABLE 95 JAPAN MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 79

    TABLE 96 JAPAN MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 80

    TABLE 97 CHINA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 80

    TABLE 98 CHINA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 80

    TABLE 99 CHINA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 81

    TABLE 100 CHINA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 81

    TABLE 101 CHINA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 82

    TABLE 102 INDIA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 82

    TABLE 103 INDIA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 82

    TABLE 104 INDIA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 83

    TABLE 105 INDIA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 83

    TABLE 106 INDIA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 84

    TABLE 107 AUSTRALIA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 84

    TABLE 108 AUSTRALIA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 84

    TABLE 109 AUSTRALIA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 85

    TABLE 110 AUSTRALIA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 85

    TABLE 111 AUSTRALIA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 86

    TABLE 112 REPUBLIC OF KOREA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 86

    TABLE 113 REPUBLIC OF KOREA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 86

    TABLE 114 REPUBLIC OF KOREA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 87

    TABLE 115 REPUBLIC OF KOREA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 87

    TABLE 116 REPUBLIC OF KOREA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 88

    TABLE 117 REST OF ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 88

    TABLE 118 REST OF ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 88

    TABLE 119 REST OF ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 89

    TABLE 120 REST OF ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 89

    TABLE 121 REST OF ASIA-PACIFIC MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 90

    TABLE 122 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY REGION 2020-2027 (USD MILLION) 91

    TABLE 123 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 91

    TABLE 124 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 92

    TABLE 125 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 92

    TABLE 126 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 92

    TABLE 127 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 93

    TABLE 128 UNITED ARAB EMIRATES MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 94

    TABLE 129 UNITED ARAB EMIRATES MYOCARDIAL ISCHEMIA MARKET:BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 94

    TABLE 130 UNITED ARAB EMIRATES MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 94

    TABLE 131 UNITED ARAB EMIRATES MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 95

    TABLE 132 UNITED ARAB EMIRATES MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 96

    TABLE 133 SAUDI ARABIA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 96

    TABLE 134 SAUDI ARABIA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 96

    TABLE 135 SAUDI ARABIA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 97

    TABLE 136 SAUDI ARABIA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 97

    TABLE 137 SAUDI ARABIA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 98

    TABLE 138 OMAN MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 98

    TABLE 139 OMAN MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 98

    TABLE 140 OMAN MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 99

    TABLE 141 OMAN MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 99

    TABLE 142 OMAN MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 100

    TABLE 143 KUWAIT MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 100

    TABLE 144 KUWAIT MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 100

    TABLE 145 KUWAIT MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 101

    TABLE 146 KUWAIT MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 101

    TABLE 147 KUWAIT MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 102

    TABLE 148 QATAR MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 102

    TABLE 149 QATAR MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020-2027 (USD MILLION) 102

    TABLE 150 QATAR MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 103

    TABLE 151 QATAR MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 103

    TABLE 152 QATAR MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 104

    TABLE 153 REST OF THE MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020-2027 (USD MILLION) 105

    TABLE 154 REST OF THE MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS

    2020-2027 (USD MILLION) 105

    TABLE 155 REST OF THE MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY DIAGNOSIS TYPE 2020-2027 (USD MILLION) 105

    TABLE 156 REST OF THE MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT TYPE 2020-2027 (USD MILLION) 106

    TABLE 157 REST OF THE MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020-2027 (USD MILLION) 107

    14 List Of Figures

    FIGURE 1 MARKET STRUCTURE 17

    FIGURE 2 RESEARCH PROCESS 19

    FIGURE 3 DROC ANALYSIS OF GLOBAL MYOCARDIAL ISCHEMIA MARKET: 22

    FIGURE 4 DRIVERS IMPACT ANALYSIS: GLOBAL MYOCARDIAL ISCHEMIA MARKET: 23

    FIGURE 5 RESTRAINTS IMPACT ANALYSIS: GLOBAL MYOCARDIAL ISCHEMIA MARKET: 24

    FIGURE 6 VALUE CHAIN: GLOBAL MYOCARDIAL ISCHEMIA MARKET: 27

    FIGURE 7 PORTER’S FIVE FORCES MODEL: GLOBAL MYOCARDIAL ISCHEMIA MARKET: 28

    FIGURE 8 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY TYPE 2020 & 2027 (USD MILLION) 32

    FIGURE 9 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY TREATMENT & DIAGNOSIS 2020 & 2027 (USD MILLION) 35

    FIGURE 10 GLOBAL MYOCARDIAL ISCHEMIA MARKET: BY END USER 2020 & 2027 (USD MILLION) 39

    FIGURE 11 GLOBAL MYOCARDIAL ISCHEMIA MARKET: SHARE BY REGION 2020 (%) 42

    FIGURE 12 AMERICAS MYOCARDIAL ISCHEMIA MARKET SHARE BY REGION 2020 (%) 43

    FIGURE 13 EUROPE MYOCARDIAL ISCHEMIA MARKET SHARE BY REGION 2020 (%) 55

    FIGURE 14 ASIA PACIFIC MYOCARDIAL ISCHEMIA MARKET SHARE BY REGION 2020 (%) 75

    FIGURE 15 MIDDLE EAST & AFRICA MYOCARDIAL ISCHEMIA MARKET SHARE BY REGION 2020 (%) 91

    FIGURE 16 GLOBAL MYOCARDIAL ISCHEMIA MARKET: SHARE ANALYSIS 2020 (%) 109

    Global Myocardial Ischemia Market: Competitive Landscape


    Numerous players are operating in this market all over the globe. Many organizations especially in the American, European, and Asian regions have their manufacturing units, while some organizations outsource their facility of manufacturing to other organizations. As there are plenty of large and small market players available, it is  very tricky to analyze their market shares.


    The global market for myocardial ischemia is majorly dominated by companies including Boston Scientific, Inc., Edward Lifesciences, Johnson and Johnson Services Inc. (Janssen Global Services, LLC.), and Pfizer Inc. which accounts for ~19.3% of the market.


    Boston Scientific Inc. is the leader in the global myocardial ischemia market and is estimated to hold approximately, 8.10% of the total market. Boston Scientific, Inc has a vast product portfolio in the myocardial ischemia industry. The company also has a wide geographic presence as it operates in various countries across the world. It has a significant presence in North America, Europe, and the Middle East and Africa, with commercial, manufacturing, and research facilities in more than one dozen countries. The company is focusing on expanding the category leadership and driving the growth globally. It is also advancing in patient care and delivering strong financial performance.


    In June 2017, Edward Lifesciences followed the leadership of Boston Scientific Inc. and stood second. The company held 5.20% of the total market share. The company pioneers in the science of heart valves and hemodynamic monitoring. The company partners with medical practitioners to develop new technologies for the treatment of structural heart disease and critical care monitoring. It is advancing its innovations to develop efficient products to transform the patient care. For instance, in February 2018, Edwards Lifesciences Corporation received the CE Mark for its self-expanding CENTERA valve, thus enhancing its transcatheter heart valve therapy segment.


    Johnson & Johnson Services Inc. (Janssen Global Services, LLC) stood third in the global myocardial ischemia market in 2017 with a share of 3.80%. The company is aimed at creating a world without disease by transforming lives through new and better ways to prevent, intercept, treat, and cure diseases. The company focuses on increasing investments in R&D to produce more innovative products. As a result, in June 2018, the Janssen Pharmaceutical Companies of Johnson & Johnson announced new findings from two real-world studies comparing sodium glucose co-transporter-2 inhibitor (SGLT2i) INVOKANA (canagliflozin) and glucagon-like peptide-1 receptor agonists (GLP-1s) in treating adults with type 2 diabetes.


    Apart from these major players, there are many small scaled companies which operate in the myocardial ischemia market. These companies manufacture various types of medical devices and robotic products and majorly operate in specific regions and countries. Some of these companies include Taxus Cardium and ViroMed Co. Ltd., among others.


    New product launches, product approvals, and product enhancements are the primary growth strategies adopted by major players to enhance their positions in the global market for myocardial ischemia.


    Moreover, strategies such as partnerships, agreements, and collaborations, geographic expansions,  and acquisitions were also adopted by a significant number of market players to strengthen their product portfolios and expand their geographic presence in the market.